vs
Side-by-side financial comparison of Pulmonx Corp (LUNG) and Village Farms International, Inc. (VFF). Click either name above to swap in a different company.
Pulmonx Corp is the larger business by last-quarter revenue ($20.6M vs $12.2M, roughly 1.7× Village Farms International, Inc.). Village Farms International, Inc. runs the higher net margin — 19.9% vs -66.3%, a 86.2% gap on every dollar of revenue. On growth, Village Farms International, Inc. posted the faster year-over-year revenue change (31.5% vs -8.7%).
Pulmonx Corp is a global medical tech firm focused on interventional pulmonology solutions. It develops minimally invasive endobronchial valves to treat severe COPD and emphysema, with products sold across North America, Europe, and Asia-Pacific for patients with advanced lung conditions.
Grafton Village Cheese Company is a cheesemaker in the town of Grafton in the U.S. state of Vermont. The company produces hand-crafted aged cheddar cheese.
LUNG vs VFF — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $20.6M | $12.2M |
| Net Profit | $-13.7M | $2.4M |
| Gross Margin | 77.9% | — |
| Operating Margin | -40.9% | — |
| Net Margin | -66.3% | 19.9% |
| Revenue YoY | -8.7% | 31.5% |
| Net Profit YoY | 5.5% | 128.2% |
| EPS (diluted) | $-0.33 | $0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $20.6M | — | ||
| Q4 25 | $22.6M | $12.2M | ||
| Q3 25 | $21.5M | $66.7M | ||
| Q2 25 | $23.9M | $59.9M | ||
| Q1 25 | $22.5M | $77.1M | ||
| Q4 24 | $23.8M | — | ||
| Q3 24 | $20.4M | $54.9M | ||
| Q2 24 | $20.8M | $53.6M |
| Q1 26 | $-13.7M | — | ||
| Q4 25 | $-10.4M | $2.4M | ||
| Q3 25 | $-14.0M | $10.2M | ||
| Q2 25 | $-15.2M | $26.5M | ||
| Q1 25 | $-14.4M | $-6.7M | ||
| Q4 24 | $-13.2M | — | ||
| Q3 24 | $-14.1M | $-820.0K | ||
| Q2 24 | $-15.3M | $-23.5M |
| Q1 26 | 77.9% | — | ||
| Q4 25 | 77.6% | — | ||
| Q3 25 | 74.7% | 47.9% | ||
| Q2 25 | 72.1% | 37.3% | ||
| Q1 25 | 72.5% | 14.7% | ||
| Q4 24 | 74.0% | — | ||
| Q3 24 | 73.7% | 24.8% | ||
| Q2 24 | 73.7% | 25.4% |
| Q1 26 | -40.9% | — | ||
| Q4 25 | -43.8% | — | ||
| Q3 25 | -66.9% | 23.3% | ||
| Q2 25 | -62.0% | 20.8% | ||
| Q1 25 | -64.6% | -8.0% | ||
| Q4 24 | -56.5% | — | ||
| Q3 24 | -69.3% | 3.8% | ||
| Q2 24 | -75.2% | -43.5% |
| Q1 26 | -66.3% | — | ||
| Q4 25 | -46.1% | 19.9% | ||
| Q3 25 | -64.9% | 15.3% | ||
| Q2 25 | -63.6% | 44.2% | ||
| Q1 25 | -64.1% | -8.7% | ||
| Q4 24 | -55.4% | — | ||
| Q3 24 | -69.4% | -1.5% | ||
| Q2 24 | -73.7% | -43.9% |
| Q1 26 | $-0.33 | — | ||
| Q4 25 | $-0.25 | $0.01 | ||
| Q3 25 | $-0.34 | $0.08 | ||
| Q2 25 | $-0.38 | $0.24 | ||
| Q1 25 | $-0.36 | $-0.06 | ||
| Q4 24 | $-0.33 | — | ||
| Q3 24 | $-0.36 | $-0.01 | ||
| Q2 24 | $-0.39 | $-0.21 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $61.6M | $81.2M |
| Total DebtLower is stronger | $37.3M | $33.7M |
| Stockholders' EquityBook value | $45.8M | $299.9M |
| Total Assets | $120.0M | $423.1M |
| Debt / EquityLower = less leverage | 0.82× | 0.11× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $61.6M | — | ||
| Q4 25 | $69.8M | $81.2M | ||
| Q3 25 | $76.5M | $82.6M | ||
| Q2 25 | $75.5M | $60.0M | ||
| Q1 25 | $74.6M | $15.1M | ||
| Q4 24 | $70.9M | — | ||
| Q3 24 | $63.3M | $28.7M | ||
| Q2 24 | $63.5M | $29.7M |
| Q1 26 | $37.3M | — | ||
| Q4 25 | $37.1M | $33.7M | ||
| Q3 25 | $37.1M | $34.6M | ||
| Q2 25 | $37.1M | $39.1M | ||
| Q1 25 | $37.2M | $39.2M | ||
| Q4 24 | $37.2M | — | ||
| Q3 24 | $37.2M | $43.3M | ||
| Q2 24 | $37.2M | $44.4M |
| Q1 26 | $45.8M | — | ||
| Q4 25 | $54.1M | $299.9M | ||
| Q3 25 | $60.0M | $295.4M | ||
| Q2 25 | $69.1M | $284.3M | ||
| Q1 25 | $77.7M | $248.3M | ||
| Q4 24 | $85.8M | — | ||
| Q3 24 | $93.9M | $274.4M | ||
| Q2 24 | $101.2M | $275.2M |
| Q1 26 | $120.0M | — | ||
| Q4 25 | $129.3M | $423.1M | ||
| Q3 25 | $138.3M | $418.4M | ||
| Q2 25 | $147.2M | $403.7M | ||
| Q1 25 | $150.7M | $377.1M | ||
| Q4 24 | $162.8M | — | ||
| Q3 24 | $167.4M | $417.8M | ||
| Q2 24 | $172.6M | $425.4M |
| Q1 26 | 0.82× | — | ||
| Q4 25 | 0.69× | 0.11× | ||
| Q3 25 | 0.62× | 0.12× | ||
| Q2 25 | 0.54× | 0.14× | ||
| Q1 25 | 0.48× | 0.16× | ||
| Q4 24 | 0.43× | — | ||
| Q3 24 | 0.40× | 0.16× | ||
| Q2 24 | 0.37× | 0.16× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LUNG
Segment breakdown not available.
VFF
| International Sales | $8.7M | 71% |
| Cannabis United States Segment | $3.4M | 27% |
